A
Ashley M. Hughes
Researcher at GlaxoSmithKline
Publications - 12
Citations - 1496
Ashley M. Hughes is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Histone H3 & Mutation. The author has an hindex of 11, co-authored 12 publications receiving 1213 citations.
Papers
More filters
Journal ArticleDOI
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
Michael T. McCabe,Alan P. Graves,Gopinath Ganji,Elsie Diaz,Wendy S. Halsey,Yong Jiang,Kimberly N. Smitheman,Heidi M. Ott,Melissa B. Pappalardi,Kimberly E. Allen,Stephanie Chen,Anthony Della Pietra,Edward Dul,Ashley M. Hughes,Seth A. Gilbert,Sara H. Thrall,Peter J. Tummino,Ryan G. Kruger,Martin Brandt,Benjamin J. Schwartz,Caretha L. Creasy +20 more
TL;DR: This mutation highlights the interplay between Y641 and A677 residues in the substrate specificity of EZH2 and identifies another lymphoma patient population that harbors an activating mutation of EzH2.
Journal ArticleDOI
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
James G. Greger,Stephen Eastman,Vivian Zhang,Maureen R. Bleam,Ashley M. Hughes,Kimberly N. Smitheman,Scott Howard Dickerson,Sylvie Laquerre,Li Liu,Tona M. Gilmer +9 more
TL;DR: The results show that NRAS and/or MEK mutations contribute to BRAF inhibitor resistance in vitro, and the combination of GSK2118436 and GSK1120212 overcomes this resistance.
Journal ArticleDOI
Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments.
Jun Yu,Sabyasachi Bhattacharya,Niranjan Yanamandra,David J. Kilian,Hong Shi,Sapna Yadavilli,Yuliya V. Katlinskaya,Heather Kaczynski,Michael Conner,William G. Benson,Ashleigh Hahn,Laura M. Seestaller-Wehr,Meixia Bi,Nicholas J. Vitali,Lyuben Tsvetkov,Wendy S. Halsey,Ashley M. Hughes,Christopher M. Traini,Hui Zhou,Junping Jing,Tae Lee,David J. Figueroa,Sara Brett,Christopher B. Hopson,James F. Smothers,Axel Hoos,Roopa Srinivasan +26 more
TL;DR: The tumor microenvironment of four commonly used mouse syngeneic tumor models is characterized and it is proposed each model possesses a unique tumor-immune infiltrate profile that can be probed with immunotherapies to inform on anti-tumor mechanisms and treatment strategies in human tumors with similar profiles.
Journal ArticleDOI
Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes
Weihua Zhao,David R. Beers,Kristopher G Hooten,Douglas H. Sieglaff,Aijun Zhang,Shanker Kalyana-Sundaram,Christopher M. Traini,Wendy S. Halsey,Ashley M. Hughes,Ganesh M. Sathe,George P. Livi,Guo Huang Fan,Stanley H. Appel +12 more
TL;DR: The data indicate that ALS monocytes are skewed toward a proinflammatory state in the peripheral circulation and may play a role in ALS disease progression, especially in rapidly progressing patients.
Journal ArticleDOI
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Jonathan Welti,Adam Sharp,Wei Yuan,David Dolling,Daniel Nava Rodrigues,Ines Figueiredo,Veronica Gil,Antje Neeb,Matthew Clarke,George Seed,Mateus Crespo,Semini Sumanasuriya,Jian Ning,Eleanor Knight,Jeffrey C. Francis,Ashley M. Hughes,Wendy S. Halsey,Alec Paschalis,Ram Shankar Mani,Ganesh V. Raj,Stephen R. Plymate,Suzanne Carreira,Gunther Boysen,Arul M. Chinnaiyan,Amanda Swain,Johann S. de Bono +25 more
TL;DR: BETi merit clinical evaluation as inhibitors of AR splicing and function, with trials demonstrating their blockade in proof-of-mechanism pharmacodynamic studies.